Headquarters
9 TRAFALGAR CV, LITTLE ROCK, AR 72210-3706, US
LITTLE ROCK, AR, US
KURIA THERAPEUTICS, INC.
From the company
Kuria Therapeutics is a pharmaceutical company developing a platform of novel NRF2 activators to treat blinding ophthalmic diseases. Its lead candidate, KTX-1161, is a preservative-free topical ophthalmic formulation of SCO-116, a small-molecule NRF2 activator, being advanced through IND-enabling development for Fuchs' endothelial corneal dystrophy.
Products & services offered
Capabilities 3
Facilities
Send your requirements
Quantities, certifications, and timing.